ERBB2 and breast carcinoma: This may result from the effects of these cells during the analytic in vitro culture used here, but also suggests a potentially similar mechanism in vivo. To the best of our knowledge, this is the first study on older breast cancer patients showing an advantage of having a CD8+ T cell response to Her2 and at the same time showing the possible negative role played by MDSCs and Tregs.